IL17A and chronic asthma: Currently, clinical phase II investigations are determining the effectiveness and stability of secukinumab (humanized mAb against IL-17A) and brodalumab (humanized mAb working specifically against the IL-17 receptor) in individuals with chronic asthma that is not satisfactorily managed by inhaled β2-sympathomimetics and corticosteroids [250].